Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:IOVA 3 November 2025 - 23 December 2025

Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025)

Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025)

Iovance Biotherapeutics shares jumped 12.1% to close at $2.78 on Dec. 22, with pre-market trading near $2.80. Short interest stands at 33.4% of the float, or about 118.94 million shares, according to MarketBeat. Barclays raised its price target to $10 and kept an Overweight rating. Iovance also announced inducement stock options for four new employees at a $2.46 exercise price.
23 December 2025
Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics reported Q3 2025 revenue of $67.5 million, up 13% sequentially but below analyst expectations, and a net loss of $91.3 million, or $0.25 per share. Gross margin rose to 43%. Management reaffirmed full-year revenue guidance of $250–$300 million. Over 80 U.S. treatment centers are now active, and cash reserves totaled $307 million at quarter’s end.
6 November 2025
···
Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Iovance shares traded near $2.00 on Nov. 3, 2025, with a market cap around $700 million after plunging 70% year-to-date. The company’s Amtagvi, the first FDA-approved TIL therapy for advanced melanoma, also secured Health Canada approval. Interim Phase 2 data showed a 25.6% response rate for lifileucel in advanced NSCLC. Iovance will hold its Q3 earnings call on Nov. 6.
3 November 2025

Stock Market Today

  • Evertz Technologies Fair Value Targets Lifted by Analysts on TSX
    March 20, 2026, 2:37 PM EDT. Analysts have raised the fair value estimate for Evertz Technologies (TSX:ET) from CA$14.88 to CA$17.25, reflecting a roughly 16% increase and aligning with a cluster of price targets between CA$16 and CA$17.50. Canaccord and BMO Capital have each lifted their price targets to CA$17.50, maintaining positive ratings, while RBC Capital has raised its target incrementally to CA$16 but retains a cautious Sector Perform stance. The upward revisions follow updated assumptions, including a slight dip in revenue growth to 4.16% and an improved net profit margin to 12.98%. The stock's quarterly dividend was declared at CA$0.2050 per share, payable March 2026. Investors should note the narrowed upside range and potential risks flagged, advising careful consideration of entry points and expectations.
Go toTop